Albany Molecular Research, Inc. (AMRI)

[surf1944]

8:17AM Albany Molecular announces development and manufacturing deal with Biota Holdings (AMRI) 2.80 : Co was selected by Biota Holdings, an anti-infective drug development company based in Australia, to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. AMRI will provide these services to support a New Drug Application for laninamivir to the FDA. AMRI's role will initially involve the development and manufacture of the active pharmaceutical ingredient for use in clinical trials. In the future there is the potential for AMRI to be selected as the commercial manufacturer of the product.